Jefferies on Celcuity Inc (CELC): 'we believe everolimus+gire could be a good option specifically for the PIK3CAwt/ESR1mut subgrp'
Tweet Send to a Friend
Jefferies analyst Maury Raycroft reiterated a Buy rating and $108.00 price target on Celcuity Inc (NASDAQ: CELC).The analyst comments "The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
